Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial
Key Points
Key points are not available for this paper at this time.
Abstract
Valneva, Coalition for Epidemic Preparedness Innovation, and EU Horizon 2020.
Demander à l'IA
Like
Bookmark
Share
View Full Paper
Demander à l'IA
Like
Bookmark
Share
View Full Paper
Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial | Synapse